blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2870261

EP2870261 - BIOMARKERS ASSOCIATED WITH CDK INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.10.2018
Database last updated on 25.09.2024
FormerThe patent has been granted
Status updated on  03.11.2017
FormerGrant of patent is intended
Status updated on  21.06.2017
FormerExamination is in progress
Status updated on  25.11.2016
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL, IS		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
For all designated states
Dana-Farber Cancer Institute, Inc.
450 Brookline Avenue
Boston, MA 02215-5450 / US
For all designated states
Broad Institute
44 Binney Street
Boston, Massachusetts 02115 / US
[2015/20]
Inventor(s)01 / CAPONIGRO, Giordano
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, MA 02139 / US
02 / DELACH, Scott
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, MA 02139 / US
03 / GARRAWAY, Levi
Dana-Farber Cancer Institute Inc.
450 Brookline Avenue
Boston, MA 02215-5450 / US
04 / JAGANI, Zainab
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, MA 02139 / US
05 / KIM, Sunkyu
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, MA 02139 / US
06 / KRYUKOV, Gregory
Broad Institute, Inc.
7 Cambridge Center
Cambridge, MA 02143 / US
 [2015/20]
Representative(s)Bucher, Tamaris Clare, et al
Novartis Pharma AG
Patent Department
4002 Basel / CH
[N/P]
Former [2015/20]Kassow, Anders, et al
Novartis Pharma AG
Patent Department
4002 Basel / CH
Application number, filing date13735529.326.06.2013
[2017/49]
WO2013US47925
Priority number, dateUS201261669534P09.07.2012         Original published format: US 201261669534 P
[2015/20]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014011398
Date:16.01.2014
Language:EN
[2014/03]
Type: A1 Application with search report 
No.:EP2870261
Date:13.05.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 16.01.2014 takes the place of the publication of the European patent application.
[2015/20]
Type: B1 Patent specification 
No.:EP2870261
Date:06.12.2017
Language:EN
[2017/49]
Search report(s)International search report - published on:EP16.01.2014
ClassificationIPC:C12Q1/68
[2015/20]
CPC:
C12Q1/6886 (EP,CN,US); A61K31/454 (EP,US); A61K31/506 (EP,US);
A61K31/519 (EP,US); A61P35/00 (EP); A61P35/02 (EP);
A61P43/00 (EP); G01N33/5011 (US); G01N33/57496 (US);
C12Q2600/106 (EP,CN,US); C12Q2600/156 (EP,CN,US); C12Q2600/158 (EP,CN,US);
C12Q2600/16 (US); G01N2333/4739 (US); G01N2440/14 (US);
G01N2500/04 (US); G01N2500/10 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/20]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:MIT CDK-INHIBITOREN ASSOZIIERTE BIOMARKER[2015/20]
English:BIOMARKERS ASSOCIATED WITH CDK INHIBITORS[2015/20]
French:BIOMARQUEURS ASSOCIES AUX INHIBITEURS DE KINASES CYCLINE-DEPENDANTES.[2017/28]
Former [2015/20]BIOMARQUEURS ASSOCIÉS À DES INHIBITEURS DE CDK
Entry into regional phase09.02.2015National basic fee paid 
09.02.2015Designation fee(s) paid 
09.02.2015Examination fee paid 
Examination procedure09.02.2015Examination requested  [2015/20]
10.08.2015Amendment by applicant (claims and/or description)
17.05.2016Despatch of a communication from the examining division (Time limit: M06)
24.11.2016Reply to a communication from the examining division
21.03.2017Despatch of a communication from the examining division (Time limit: M02)
23.05.2017Reply to a communication from the examining division
22.06.2017Communication of intention to grant the patent
27.10.2017Fee for grant paid
27.10.2017Fee for publishing/printing paid
27.10.2017Receipt of the translation of the claim(s)
Divisional application(s)EP17198700.1  / EP3309263
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  17.05.2016
Opposition(s)07.09.2018No opposition filed within time limit [2018/46]
Fees paidRenewal fee
10.06.2015Renewal fee patent year 03
10.06.2016Renewal fee patent year 04
16.06.2017Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU26.06.2013
AL06.12.2017
AT06.12.2017
CY06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
FI06.12.2017
HR06.12.2017
LT06.12.2017
LV06.12.2017
MC06.12.2017
MK06.12.2017
NL06.12.2017
PL06.12.2017
PT06.12.2017
RO06.12.2017
RS06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
TR06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
IS06.04.2018
IE26.06.2018
LU26.06.2018
MT26.06.2018
BE30.06.2018
CH30.06.2018
LI30.06.2018
[2020/33]
Former [2020/31]HU26.06.2013
AT06.12.2017
CY06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
FI06.12.2017
HR06.12.2017
LT06.12.2017
LV06.12.2017
MC06.12.2017
MK06.12.2017
NL06.12.2017
PL06.12.2017
PT06.12.2017
RO06.12.2017
RS06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
TR06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
IE26.06.2018
LU26.06.2018
MT26.06.2018
BE30.06.2018
CH30.06.2018
LI30.06.2018
Former [2020/30]HU26.06.2013
AT06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
FI06.12.2017
HR06.12.2017
LT06.12.2017
LV06.12.2017
MC06.12.2017
NL06.12.2017
PL06.12.2017
PT06.12.2017
RO06.12.2017
RS06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
TR06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
IE26.06.2018
LU26.06.2018
MT26.06.2018
BE30.06.2018
CH30.06.2018
LI30.06.2018
Former [2020/28]AT06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
FI06.12.2017
HR06.12.2017
LT06.12.2017
LV06.12.2017
MC06.12.2017
NL06.12.2017
PL06.12.2017
PT06.12.2017
RO06.12.2017
RS06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
TR06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
IE26.06.2018
LU26.06.2018
MT26.06.2018
BE30.06.2018
CH30.06.2018
LI30.06.2018
Former [2020/16]AT06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
FI06.12.2017
HR06.12.2017
LT06.12.2017
LV06.12.2017
MC06.12.2017
NL06.12.2017
PL06.12.2017
RO06.12.2017
RS06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
TR06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
IE26.06.2018
LU26.06.2018
MT26.06.2018
BE30.06.2018
CH30.06.2018
LI30.06.2018
Former [2020/08]AT06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
FI06.12.2017
HR06.12.2017
LT06.12.2017
LV06.12.2017
MC06.12.2017
NL06.12.2017
PL06.12.2017
RO06.12.2017
RS06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
IE26.06.2018
LU26.06.2018
MT26.06.2018
BE30.06.2018
CH30.06.2018
LI30.06.2018
Former [2019/24]AT06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
FI06.12.2017
HR06.12.2017
LT06.12.2017
LV06.12.2017
MC06.12.2017
NL06.12.2017
PL06.12.2017
RO06.12.2017
RS06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
IE26.06.2018
LU26.06.2018
BE30.06.2018
CH30.06.2018
LI30.06.2018
Former [2019/21]AT06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
FI06.12.2017
HR06.12.2017
LT06.12.2017
LV06.12.2017
MC06.12.2017
NL06.12.2017
PL06.12.2017
RO06.12.2017
RS06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
IE26.06.2018
LU26.06.2018
CH30.06.2018
LI30.06.2018
Former [2019/19]AT06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
FI06.12.2017
HR06.12.2017
LT06.12.2017
LV06.12.2017
MC06.12.2017
NL06.12.2017
PL06.12.2017
RO06.12.2017
RS06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
IE26.06.2018
LU26.06.2018
Former [2019/17]AT06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
FI06.12.2017
HR06.12.2017
LT06.12.2017
LV06.12.2017
MC06.12.2017
NL06.12.2017
PL06.12.2017
RO06.12.2017
RS06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
LU26.06.2018
Former [2019/15]AT06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
FI06.12.2017
HR06.12.2017
LT06.12.2017
LV06.12.2017
MC06.12.2017
NL06.12.2017
PL06.12.2017
RO06.12.2017
RS06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
Former [2018/52]AT06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
FI06.12.2017
HR06.12.2017
LT06.12.2017
LV06.12.2017
NL06.12.2017
PL06.12.2017
RO06.12.2017
RS06.12.2017
SE06.12.2017
SI06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
Former [2018/51]AT06.12.2017
CZ06.12.2017
DK06.12.2017
EE06.12.2017
FI06.12.2017
HR06.12.2017
LT06.12.2017
LV06.12.2017
NL06.12.2017
PL06.12.2017
RO06.12.2017
RS06.12.2017
SE06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
Former [2018/40]AT06.12.2017
CZ06.12.2017
EE06.12.2017
FI06.12.2017
HR06.12.2017
LT06.12.2017
LV06.12.2017
NL06.12.2017
PL06.12.2017
RO06.12.2017
RS06.12.2017
SE06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
Former [2018/38]AT06.12.2017
CZ06.12.2017
EE06.12.2017
FI06.12.2017
HR06.12.2017
LT06.12.2017
LV06.12.2017
NL06.12.2017
PL06.12.2017
RS06.12.2017
SE06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
Former [2018/37]CZ06.12.2017
EE06.12.2017
FI06.12.2017
HR06.12.2017
LT06.12.2017
LV06.12.2017
NL06.12.2017
PL06.12.2017
RS06.12.2017
SE06.12.2017
SK06.12.2017
SM06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
Former [2018/34]FI06.12.2017
HR06.12.2017
LT06.12.2017
LV06.12.2017
NL06.12.2017
RS06.12.2017
SE06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
Former [2018/24]FI06.12.2017
HR06.12.2017
LT06.12.2017
LV06.12.2017
RS06.12.2017
SE06.12.2017
BG06.03.2018
NO06.03.2018
GR07.03.2018
Former [2018/22]FI06.12.2017
LT06.12.2017
NO06.03.2018
Cited inInternational search[I]WO2009150491  (PIRAMAL LIFE SCIENCES LTD [IN], et al) [I] 1-36 * claims 1,2 * * abstract *
 [I]  - ANA-TERESA MAIA ET AL, "Extent of differential allelic expression of candidate breast cancer genes is similar in blood and breast", BREAST CANCER RESEARCH, (20090101), vol. 11, no. 6, doi:10.1186/bcr2458, ISSN 1465-5411, page R88, XP055018549 [I] 37 * abstract * * the whole document *

DOI:   http://dx.doi.org/10.1186/bcr2458
Examination   - AFFYMETRIX, "Data Sheet Affymetrix(R) Genome-Wide Human SNP Array 6.0", INTERNET CITATION, (2007), pages 1 - 4, URL: http://www.affymetrix.com/support/technical/datasheets/genomewide_snp6_datasheet.pdf, (20090410), XP002525407
    - K. E. Berquam-Vrieze ET AL, "Cell of origin strongly influences genetic selection in a mouse model of T-ALL", Blood, US, (20110809), vol. 118, no. 17, doi:10.1182/blood-2011-03-343947, ISSN 0006-4971, pages 4646 - 4656, XP055271697

DOI:   http://dx.doi.org/10.1182/blood-2011-03-343947
by applicantWO9710365
 US5405783
 US5412087
 US5445934
 US4683195
 US4683203
 US5578832
 US5631734
 US3817837
 US3850752
 US3939350
 US3996345
 US4277437
 US4275149
 US4366241
    - XIONG ET AL., GENOMICS, (1992), vol. 13, pages 575 - 584
    - MOTOKURA ET AL., J. BIOL. CHEM., (1992), vol. 267, pages 20412 - 20415
    - BATES ET AL., ONCOGENE, (1994), vol. 9, pages 71 - 79
    - SHERR, TRENDS IN BIO.SCI, (1995), vol. 20, no. 5, pages 187 - 190
    - SAVAS ET AL., OMICS, (2007), vol. 11, no. 2, pages 200 - 208
    - SICINSKA ET AL., CANCER CELL, (2003), vol. 4, no. 6, pages 451 - 461
    - PASQUALUCCI ET AL., NATURE GENETICS, (2011), vol. 43, no. 9, pages 830 - 837
    - MORIN, NATURE, (2011), vol. 476, pages 298 - 303
    - SAIKI ET AL., SCIENCE, (1988), vol. 239, page 487
    - ORITA ET AL., PNAS, (1989), vol. 86, pages 2766 - 2770
    - LUCA ET AL., PNAS USA, (1986), vol. 83, no. 4
    - "Hybridization with Nucleic Acid Probes", Laboratory Techniques in Biochemistry and Molecular Biology, ELSEVIER, (1993), vol. 24
    - BARRETINA J.; CAPONIGRO G. ET AL., "The Cancer Cell Line Encyclopedia: using preclinical models to predict anticancer drug sensitivity", NATURE, (2012), vol. 483, no. 7391, pages 603 - 607
    - LI ET AL., BIOINFORMATICS, (2010), vol. 25, pages 1754 - 60
    - DEPRISTO ET AL., NAT GENET, (2011), vol. 43, pages 491 - 8
    - SHERRY ET AL., NUCLEIC ACIDS RES, (2001), vol. 29, pages 308 - 11
    - FRY ET AL., MOL. CANCER THER., (2004), vol. 3, no. 11, pages 1427 - 1438
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.